Practical fecal calprotectin cut-off value for Japanese patients with ulcerative colitis

Table 2 Clinical characteristics of relapsed and non-relapsed patients n (%)

Parameter	Relapsed patients (n = 19)	Non-relapsed patients (n = 69)	P value
Age, yr, median (IQR)	35 (23-53)	40 (29-52)	0.26
Male/female	6/13	37/32	0.08
Actual disease extent
Proctitis	5 (26.3)	18 (26.1)	0.53
Left-sided colitis	1 (5.3)	12 (17.4)
Total colitis	13 (68.4)	38 (55.1)
Segmental colitis	0 (0)	1 (1.4)
Laboratory data
WBC, /μL, median (IQR)	6130 (5110-7745)	5585 (4640-7013)	0.48
CRP, mg/dL, median (IQR)	0.05 (0.01-0.10)	0.1 (0.04-0.14)	0.05
ESR, mm/h, median (IQR)	6 (4-8)	5 (3.0-10.0)	0.69
Albumin, g/dL, median (IQR)	4.4 (4.3-4.6)	4.4 (4.1-4.6)	0.75
Hemoglobin, g/dL, median (IQR)	13.3 (12.3-14.4)	13.9 (12.6-14.9)	0.25
Platelets, × 1000/μL, median (IQR)	238 (214-339)	256 (213-294)	0.92
FC, μg/g, median (IQR)	303 (94-846)	126 (55.5-485)	0.05
Medication
Mesalazine, oral	14 (73.7)	64 (92.8)	0.03
Mesalazine, topical	1 (5.3)	3 (4.3)	0.87
Immunomodulators	6 (31.6)	18 (26.1)	0.98
Anti-TNF	4 (21.1)	12 (17.4)	0.71
Corticosteroids	3 (15.8)	5 (7.2)	0.28

CRP: C-reactive protein; ESR: Erythrocyte sedimentation rate; FC: Fecal calprotectin; IQR: Interquartile range; TNF: Tumor necrosis factor; WBC: White blood cell.